FOR IMMEDIATE RELEASE Orthomolecular Medicine News Service, March 20, 2026

Type 2 Diabetes Revisited: Why Blood Sugar Is Not the Disease

A Three-Level Model from Glucose Control to Systems Restoration

by Richard Z. Cheng, MD, PhD
Editor-in-Chief, Orthomolecular Medicine News Service (OMNS)

Highlights

• Type 2 diabetes is not a disease of blood glucose-it is a systems-level disorder
• Glucose lowering alone does not reliably prevent cardiovascular events or mortality
• Metabolic approaches improve control but do not fully restore intracellular function
• Hyperglycemia impairs vitamin C transport, creating a functional intracellular deficiency
• This "hidden deficiency" may represent a state of cellular scurvy in diabetes
• Intracellular nutrient depletion is a key driver of oxidative stress and complications
• Effective care must progress from glucose control → metabolic regulation → systems restoration

Why This Matters

For decades, type 2 diabetes has been defined-and treated-as a disorder of elevated blood glucose.

Yet large clinical trials have shown a striking and uncomfortable truth:

Lowering blood sugar does not reliably prevent the most serious outcomes of diabetes-heart attacks, strokes, or death.

This raises a fundamental question:

What if glucose is not the disease-but a marker of a deeper systemic failure?

Abstract

Type 2 diabetes mellitus (T2DM) is conventionally managed as a disorder of hyperglycemia. However, major clinical trials such as ACCORD, ADVANCE, and VADT demonstrate that intensive glycemic control does not consistently reduce macrovascular complications or all-cause mortality. These findings indicate that hyperglycemia is not the sole driver of diabetic pathology.

From a systems medicine perspective, particularly within Integrative Orthomolecular Medicine (IOM), T2DM is a systems-level disorder involving oxidative-reductive imbalance, mitochondrial dysfunction, micronutrient depletion, hormonal dysregulation, and environmental influences.

A central and underrecognized mechanism is that hyperglycemia impairs cellular uptake of vitamin C via competitive inhibition at glucose transporters, leading to functional intracellular deficiency despite normal plasma levels. This represents a transport-level "pseudo-deficiency" that contributes to oxidative stress, endothelial dysfunction, and vascular complications.

We propose a three-level model of T2DM management:

1. Glucose-centric conventional medicine
2. Metabolic regulation via low-carbohydrate and ketogenic diets
3. IOM Systems Medicine-systems restoration

While metabolic therapies represent a major advance, they do not fully restore intracellular and systemic biological function. IOM Systems Medicine represents the next necessary level of intervention.

1. The Clinical Paradox of Glycemic Control

Despite decades of emphasis on lowering blood glucose, major clinical trials have shown limited impact on hard outcomes.

Intensive glycemic control:

• Improves some microvascular outcomes
• Does not consistently reduce macrovascular events
• Does not significantly reduce all-cause mortality

Why do complications persist even when glucose is controlled?

Because glucose is a downstream signal-not the upstream cause.

2. Type 2 Diabetes as a Systems-Level Disorder

T2DM is more accurately understood as a systems disease involving:

• Oxidative stress
• Mitochondrial dysfunction
• Chronic inflammation
• Endothelial injury
• Micronutrient depletion
• Hormonal dysregulation
• Environmental toxic burden

These processes converge through disruption of the oxidative-reductive (redox) system, forming a shared biological terrain that drives disease progression.

3. Metabolic Medicine: Role and Limitations

Low-carbohydrate and ketogenic diets represent a major advance beyond conventional glucose-centric care.

They:

• Improve glycemic control
• Reduce insulin requirements
• Can induce partial remission

However:

Metabolic control does not equal biological restoration.

Even with improved glucose markers, key dysfunctions may persist:

• Oxidative stress
• Mitochondrial dysfunction
• Intracellular micronutrient deficiency
• Hormonal imbalance
• Toxic burden

Metabolic therapy is a transition layer:
from symptom control → to metabolic regulation
but not yet → systems restoration

4. Hyperglycemia-Induced Functional Vitamin C Deficiency

A Central Mechanism of Disease

Glucose competes with vitamin C for cellular transport.

Under hyperglycemic conditions:

• Cellular vitamin C uptake is reduced
• Intracellular deficiency develops despite normal blood levels

This creates a functional deficiency-a transport problem, not an intake problem.

A New Perspective

This phenomenon is part of what we describe as the Insulin-Cortisol-Vitamin C (ICV) axis, linking glucose metabolism, hormonal signaling, and intracellular nutrient delivery.

In effect:

Diabetes may represent a state of "cellular scurvy."

5. A Self-Reinforcing Disease Loop

Hyperglycemia → ↓ intracellular vitamin C → ↑ oxidative stress → ↑ insulin resistance → worsening hyperglycemia

This feedback loop helps explain why complications persist despite glucose control.

6. The IOM Nutrient Demand Principle

A core principle:

As disease burden increases, nutrient demand increases.

In T2DM, demand rises due to:

• Oxidative stress
• Chronic inflammation
• Hyperglycemia
• Renal losses
• Medication effects

Standard dietary intake may be insufficient to restore cellular function.

7. Key Nutrient Deficiencies in Diabetes

Common deficiencies include:

• Vitamin C → impaired antioxidant defense and endothelial function
• Vitamin D → supports immune regulation, insulin function, and systemic inflammation balance
• Thiamine (B1) → impaired glucose metabolism and mitochondrial function
• Magnesium → insulin resistance and cardiovascular risk

These are not secondary findings-they are core drivers of dysfunction.

8. Hormonal and Environmental Drivers

Metabolic dysfunction is further amplified by:

• Hormonal dysregulation (insulin, cortisol, thyroid, sex hormones)
• Environmental toxic burden

These factors interact with the redox system and shape the biological terrain.

9. Toward a Systems Therapeutic Model

Effective care must integrate:

1. Dietary strategy (low-carbohydrate / ketogenic)
2. Nutritional optimization
3. Redox restoration
4. Hormonal balance
5. Toxic burden reduction

10. Three Levels of Diabetes Management

Fig. 1. A three-level model for type 2 diabetes mellitus (T2DM).
Level 1 focuses on glucose control (conventional medicine), Level 2 on metabolic correction (e.g., ketogenic diet), and Level 3 on system restoration (IOM Systems Medicine). The model illustrates progression from downstream symptom control to upstream system-level restoration.

Level 1 - Glucose Control (Conventional Medicine)

• Focus: Blood glucose
• Limitation: Targets downstream marker

Level 2 - Metabolic Regulation

• Focus: Insulin resistance
• Strength: Clinically effective
• Limitation: Incomplete restoration

Level 3 - IOM Systems Medicine

• Focus: Whole-system restoration
• Includes:
  • Nutrients
  • Redox balance
  • Mitochondria
  • Hormones
  • Environmental factors

Key insight:

Hyperglycemia is both a marker and a driver of systemic dysfunction.

🔥 Positioning Statement

Low-carbohydrate and ketogenic therapies represent a major advance in diabetes care.

But they are not the endpoint.

The next step is not better glucose control-
it is restoration of the biological system itself.

Conclusion

Type 2 diabetes is not simply a disease of high blood glucose.

It is a systems-level disorder characterized by:

• Impaired intracellular nutrient availability
• Disrupted oxidative-reductive balance
• Progressive metabolic dysfunction

While metabolic approaches address key drivers, they do not fully restore biological function.

IOM Systems Medicine provides the next step: systems restoration.

OMNS Takeaway

Focusing only on blood glucose misses the core biology of diabetes.

Effective care must address:

• Intracellular nutrient delivery
• Oxidative-reductive balance
• Whole-system function

Scientific Source

A full-length scientific version of this article has been published as a preprint:

Cheng RZ.
Type 2 Diabetes as a Systems-Level Disorder: A Root Driver Model Integrating Metabolic, Nutritional, Hormonal, and Environmental Determinants.
Preprints 2026.
https://doi.org/10.20944/preprints202604.0801.v1

Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

Find a Doctor

To locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Jennifer L. Aliano, M.S., L.Ac., C.C.N. (USA)
Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)
Ilyès Baghli, M.D. (Algeria)
Greg Beattie, Author (Australia)
Barry Breger, M.D. (Canada)
Ian Brighthope, MBBS, FACNEM (Australia)
Gilbert Henri Crussol, D.M.D. (Spain)
Carolyn Dean, M.D., N.D. (USA)
Ian Dettman, Ph.D. (Australia)
Susan R. Downs, M.D., M.P.H. (USA)
Ron Ehrlich, B.D.S. (Australia)
Hugo Galindo, M.D. (Colombia)
Gary S. Goldman, Ph.D. (USA)
William B. Grant, Ph.D. (USA)
Claus Hancke, MD, FACAM (Denmark)
Patrick Holford, BSc (United Kingdom)
Ron Hunninghake, M.D. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Dwight Kalita, Ph.D. (USA)
Felix I. D. Konotey-Ahulu, M.D., FRCP (Ghana)
Peter H. Lauda, M.D. (Austria)
Fabrice Leu, N.D., (Switzerland)
Alan Lien, Ph.D. (Taiwan)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Pedro Gonzalez Lombana, M.D., Ph.D. (Colombia)
Diana MacKay (Gifford-Jones), M.P.P. (Canada)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Juan Manuel Martinez, M.D. (Colombia)
Mignonne Mary, M.D. (USA)
Dr.Aarti Midha M.D., ABAARM (India)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Sarah Myhill, MB, BS (United Kingdom)
Tahar Naili, M.D. (Algeria)
Zhiwei Ning, M.D., Ph.D. (China)
Zhiyong Peng, M.D. (China)
Pawel Pludowski, M.D. (Poland)
Isabella Akyinbah Quakyi, Ph.D. (Ghana)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Thomas N. Seyfried, Ph.D. (USA)
Han Ping Shi, M.D., Ph.D. (China)
T.E. Gabriel Stewart, M.B.B.CH. (Ireland)
Jagan Nathan Vamanan, M.D. (India)
Dr. Sunil Wimalawansa, M.D., Ph.D. (Sri Lanka)

Andrew W. Saul, Ph.D. (USA), Founding & Former Editor
Richard Cheng, M.D., Ph.D. (USA), Editor-In-Chief
Associate Editor: Robert G. Smith, Ph.D. (USA)
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)
Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)
Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)
Editor, Spanish Edition: Sonia Rita Rial, PhD (Argentina)
Editor, German Edition: Bernhard Welker, M.D. (Germany)
Associate Editor, Arabic Edition: Ayman Kamel, DVM, MBA (Egypt)
Associate Editor, German Edition: Gerhard Dachtler, M.Eng. (Germany)
Assistant Editor: Michael Passwater (USA)
Contributing Editor: Thomas E. Levy, M.D., J.D. (USA)
Contributing Editor: Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Contributing Editor: W. Todd Penberthy, Ph.D. (USA)
Contributing Editor: Michael J. Gonzalez, N.M.D., Ph.D. (Puerto Rico)
Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)
Associate Technology Editor: Robert C. Kennedy, M.S. (USA)
Legal Consultant: Jason M. Saul, JD (USA)

Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge: https://www.orthomolecular.org/subscribe.html

To Unsubscribe from this list: https://www.orthomolecular.org/unsubscribe.html